JP2005514063A - イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法 - Google Patents

イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法 Download PDF

Info

Publication number
JP2005514063A
JP2005514063A JP2003560167A JP2003560167A JP2005514063A JP 2005514063 A JP2005514063 A JP 2005514063A JP 2003560167 A JP2003560167 A JP 2003560167A JP 2003560167 A JP2003560167 A JP 2003560167A JP 2005514063 A JP2005514063 A JP 2005514063A
Authority
JP
Japan
Prior art keywords
variable domain
chain variable
canine
cdr
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003560167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514063A5 (https=
Inventor
レギス ザ サード クラー、ユージーン
グオ、ホンリャン
アイヤッパ、アショク
ロートン、ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Idexx Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Laboratories Inc filed Critical Idexx Laboratories Inc
Publication of JP2005514063A publication Critical patent/JP2005514063A/ja
Publication of JP2005514063A5 publication Critical patent/JP2005514063A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2003560167A 2001-12-21 2002-12-20 イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法 Pending JP2005514063A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34487401P 2001-12-21 2001-12-21
PCT/US2002/041362 WO2003060080A2 (en) 2001-12-21 2002-12-20 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them

Publications (2)

Publication Number Publication Date
JP2005514063A true JP2005514063A (ja) 2005-05-19
JP2005514063A5 JP2005514063A5 (https=) 2006-01-05

Family

ID=23352425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003560167A Pending JP2005514063A (ja) 2001-12-21 2002-12-20 イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法

Country Status (6)

Country Link
US (1) US7261890B2 (https=)
EP (1) EP1485126A4 (https=)
JP (1) JP2005514063A (https=)
AU (1) AU2002359851A1 (https=)
CA (1) CA2469833C (https=)
WO (1) WO2003060080A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520999A (ja) * 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ５２に対するモノクローナル抗体
JP2013520990A (ja) * 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ２０に対するモノクローナル抗体
JP2013542716A (ja) * 2010-08-19 2013-11-28 アボット・ラボラトリーズ 抗ｎｇｆ抗体およびその使用
JP2014519317A (ja) * 2011-05-06 2014-08-14 エヌヴィーアイピー プロプライエタリー リミテッド 抗神経成長因子抗体並びに前記の製造及び使用方法
JP2014522236A (ja) * 2011-05-06 2014-09-04 エヌヴィーアイピー プロプライエタリー リミテッド 抗神経成長因子抗体並びに前記抗体の製造及び使用方法
JP2014527806A (ja) * 2011-09-06 2014-10-23 エヌヴィーアイピー プロプライエタリー リミテッド イヌ化抗体及びその製造方法
JP2015501146A (ja) * 2011-10-13 2015-01-15 エヌヴィーアイピー プロプライエタリー リミテッド イヌ／ネコｃｄ２０の結合エピトープ及び前記と結合する組成物
JP2019506146A (ja) * 2015-12-18 2019-03-07 インターベット インターナショナル ベー． フェー． ヒトおよびイヌｉｌ−４ｒアルファに対するイヌ化ヒト抗体
JP2022512638A (ja) * 2018-10-09 2022-02-07 ゲノム・リサーチ・リミテッド 動物モデル及び治療用分子

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CA2635599C (en) * 2006-01-13 2014-06-17 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
BRPI0910513B8 (pt) * 2008-07-10 2021-05-25 Toray Industries uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia
US10611835B2 (en) 2008-07-10 2020-04-07 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
AU2014200771B2 (en) * 2008-09-04 2016-05-26 Vet Therapeutics, Inc. Monoclonal antibodies
EP2411050A4 (en) * 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
WO2010128372A1 (en) 2009-05-08 2010-11-11 Allergosystem S.R.L. A device for protecting pets from allergy
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB2505352B (en) * 2011-05-06 2016-01-27 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
SI3498732T1 (sl) * 2011-05-06 2022-04-29 Zoetis Services Llc Protitelesa proti živčnemu rastnemu faktorju ter postopki za pripravo in uporabo le-teh
US9580496B2 (en) 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
CA2875783C (en) 2012-06-06 2018-12-11 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN106029697B (zh) 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
US11116795B2 (en) 2015-07-10 2021-09-14 The Trustees Of The University Of Pennsylvania Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
GB2561352B (en) * 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
US11433139B2 (en) 2018-03-16 2022-09-06 Zoetis Services Llc Peptide vaccines against interleukin-31
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
SG11202105153RA (en) 2018-11-19 2021-06-29 Biocytogen Pharmaceuticals Beijing Co Ltd Anti-pd-1 antibodies and uses thereof
WO2020176871A1 (en) * 2019-02-28 2020-09-03 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
CA3145345A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
WO2021009188A1 (en) * 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
BR112022002771A2 (pt) * 2019-08-29 2022-08-09 Kindred Biosciences Inc Anticorpos anti-il31 para uso veterinário
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
MX2023004020A (es) 2020-10-07 2023-07-07 Zoetis Services Llc Anticuerpos anti-ngf y métodos para su uso.
CA3216131A1 (en) * 2021-04-21 2022-10-27 Nicola J. MASON Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)
CA3232382A1 (en) 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof
WO2025245516A1 (en) * 2024-05-24 2025-11-27 Invetx, Inc. Anti-actrii antibodies and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0383579A (ja) * 1989-08-25 1991-04-09 Chemo Sero Therapeut Res Inst イヌ×マウスヘテロハイブリドーマおよびイヌ免疫グロブリンλ鎖の定常領域をコードする遺伝子断片
JPH03123489A (ja) * 1989-09-30 1991-05-27 Chemo Sero Therapeut Res Inst イヌ免疫グロブリンκ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JPH0440894A (ja) * 1990-06-07 1992-02-12 Chemo Sero Therapeut Res Inst イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JPH06503963A (ja) * 1990-12-19 1994-05-12 プロテイン　デザイン　ラブス，インコーポレイティド 改良ヒト化免疫グロブリン
WO2001057090A1 (en) * 2000-02-01 2001-08-09 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-ige monoclonal antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5330883A (en) 1992-06-29 1994-07-19 Lsi Logic Corporation Techniques for uniformizing photoresist thickness and critical dimension of underlying features
US5622842A (en) 1994-11-09 1997-04-22 Merck & Co., Inc. DNA encoding canine immunoglobulin A
WO1997020859A1 (en) * 1995-12-08 1997-06-12 Idexx Laboratories, Inc. Methods and compositions concerning allergy in dogs
JPH09169795A (ja) 1995-12-22 1997-06-30 Hitachi Chem Co Ltd イヌ免疫グロブリンｅペプチド断片、それをコードするｄｎａ、そのｄｎａを含む組換えベクター、その組換えベクターを含む形質転換体及び抗イヌ免疫グロブリンｅ抗体の製造法
DE69922873T2 (de) * 1998-04-09 2005-12-29 Idexx Laboratories, Inc. Spezifische Bindungsproteine zur Behandlung von Allergien beim Hund
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0383579A (ja) * 1989-08-25 1991-04-09 Chemo Sero Therapeut Res Inst イヌ×マウスヘテロハイブリドーマおよびイヌ免疫グロブリンλ鎖の定常領域をコードする遺伝子断片
JPH03123489A (ja) * 1989-09-30 1991-05-27 Chemo Sero Therapeut Res Inst イヌ免疫グロブリンκ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JPH0440894A (ja) * 1990-06-07 1992-02-12 Chemo Sero Therapeut Res Inst イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
JPH06503963A (ja) * 1990-12-19 1994-05-12 プロテイン　デザイン　ラブス，インコーポレイティド 改良ヒト化免疫グロブリン
WO2001057090A1 (en) * 2000-02-01 2001-08-09 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-ige monoclonal antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6008055176, Ｖｅｔ． Ｉｍｍｕｎｏｌ． Ｉｍｍｕｎｏｐａｔｈｏｌ．， ｖｏｌ． ８０， ｐａｇｅｓ ２５９−２７０ （２００１） *
JPN6008055193, ＢｉｏＴｅｃｈｎｉｑｕｅｓ， ｖｏｌ． ２９， ｐａｇｅｓ １２８−１３０， １３２， １３４−１３６， １３８， １４０−１４５ （２０００） *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520990A (ja) * 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ２０に対するモノクローナル抗体
JP2013520999A (ja) * 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Ｃｄ５２に対するモノクローナル抗体
JP2017000142A (ja) * 2010-03-04 2017-01-05 ベット・セラピューティクス・インコーポレイテッドＶｅｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Ｃｄ５２に対するモノクローナル抗体
JP2021052785A (ja) * 2010-08-19 2021-04-08 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
JP2013542716A (ja) * 2010-08-19 2013-11-28 アボット・ラボラトリーズ 抗ｎｇｆ抗体およびその使用
JP2017176178A (ja) * 2010-08-19 2017-10-05 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
JP2023025172A (ja) * 2010-08-19 2023-02-21 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
JP2019176857A (ja) * 2010-08-19 2019-10-17 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
JP2014519317A (ja) * 2011-05-06 2014-08-14 エヌヴィーアイピー プロプライエタリー リミテッド 抗神経成長因子抗体並びに前記の製造及び使用方法
JP2014522236A (ja) * 2011-05-06 2014-09-04 エヌヴィーアイピー プロプライエタリー リミテッド 抗神経成長因子抗体並びに前記抗体の製造及び使用方法
JP2014527806A (ja) * 2011-09-06 2014-10-23 エヌヴィーアイピー プロプライエタリー リミテッド イヌ化抗体及びその製造方法
JP2015501146A (ja) * 2011-10-13 2015-01-15 エヌヴィーアイピー プロプライエタリー リミテッド イヌ／ネコｃｄ２０の結合エピトープ及び前記と結合する組成物
JP7008020B2 (ja) 2015-12-18 2022-01-25 インターベット インターナショナル ベー． フェー． ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
JP2019506146A (ja) * 2015-12-18 2019-03-07 インターベット インターナショナル ベー． フェー． ヒトおよびイヌｉｌ−４ｒアルファに対するイヌ化ヒト抗体
JP2022512638A (ja) * 2018-10-09 2022-02-07 ゲノム・リサーチ・リミテッド 動物モデル及び治療用分子

Also Published As

Publication number Publication date
WO2003060080A3 (en) 2004-02-12
WO2003060080A2 (en) 2003-07-24
US20040181039A1 (en) 2004-09-16
EP1485126A4 (en) 2007-03-21
US7261890B2 (en) 2007-08-28
AU2002359851A1 (en) 2003-07-30
EP1485126A2 (en) 2004-12-15
AU2002359851A8 (en) 2003-07-30
CA2469833A1 (en) 2003-07-24
CA2469833C (en) 2008-05-20

Similar Documents

Publication Publication Date Title
JP2005514063A (ja) イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法
EP0939653B1 (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
EP1542725B1 (en) Method of humanizing immune system molecules
WO1997034636A9 (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
JP2023518952A (ja) 獣医用抗ｉｌ４受容体抗体
JP2021515800A (ja) インターロイキン−３１に対するペプチドワクチン
TWI900705B (zh) Ｃｄ７３的抗原結合蛋白及其應用
KR20070008578A (ko) 신규한 ＩｇＥ 에피토프의 확인
JP2024503425A (ja) 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用
CN116143926B (zh) 一种抗IL1RAcP的单域抗体及其用途
CN116162161B (zh) 一种抗il-6r的单域抗体及其用途
KR20250027598A (ko) Klrb1 결합제 및 이의 사용 방법
CN111018988B (zh) 一种抗cd19的抗体、制备方法及其应用
CN111018984B (zh) 抗ck8单克隆抗体及其应用
CN117247453A (zh) 抗CD19 scFv FMC63序列的单克隆抗体及其制备和应用
CN120137031B (zh) 一种抗cd22的单域抗体及其用途
CN111100204A (zh) 靶向cd20的抗体、其制备方法和应用
CN119306834A (zh) 一种cd33的结合分子及其用途
JP2024513746A (ja) ニューモリシンを標的とした抗原結合たんぱく質およびその応用
CN120818054A (zh) 一种抗ceacam1的单域抗体及其用途
CN121362253A (zh) 一种cd19抗体或其抗原结合片段及其用途
CN116284406A (zh) 一种pd-1结合蛋白及其应用
CN120829508A (zh) 一种cd155结合分子及其用途
CN120424216A (zh) 一种抗cd123抗体及其用途
CN120424215A (zh) 一种抗cd38的单域抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090410

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100511